![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The position statement on the management of hyperglycemia in patients with type 2 diabetes mellitus issued in 2012 by the American Diabetes Association and the European Association for the Study of Diabetes contains significant improvements over the 2009 version, including an emphasis on patient-centered care, enhanced strategies for lifestyle modification, a focus on comprehensive cardiovascular risk reduction, and increased pharmacotherapy choices. As diabetes management evolves over time, further improvements may be made in future consensus statements, including a focus on prevention and early treatment and improved glycemic control in all patients, including those with comorbidities. These goals will be achievable by waning use of therapies known to cause hypoglycemia and weight gain and the increased use of therapies that do not carry these risks.
Transparency
Declaration of funding
Editorial support for this commentary was funded by Bristol-Myers Squibb and AstraZeneca LP.
Declaration of financial/other relationships
S.S.S. discloses that he has served on advisory boards for Amylin, Eli Lilly and Company, Janssen, Sanofi-Aventis, Santarus, and Takeda and has received honoraria from Amylin Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Merck, Novo Nordisk, Santarus, and Takeda.
CMRO peer reviewers may have received honoraria for their review work. The peer reviewers on this manuscript have disclosed that they have no relevant financial relationships.
Acknowledgment
Medical writing support for the preparation of this manuscript was provided by Valerie P. Zediak PhD and Judy Fallon PharmD CMPP from Complete Healthcare Communications Inc., with funding from Bristol-Myers Squibb and AstraZeneca LP.